IPSEN news, videos and press releases
For more news please use our advanced search feature.
IPSEN - More news...
IPSEN - More news...
- Ipsen publishes its 2023 Universal Registration Document
- Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
- Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
- Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
- Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA
- Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
- Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024
- Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
- Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
- Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
- IPSEN - Buy-back programme - Art 5 of MAR - Week 43 - 2023
- Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance
- IPSEN - Buy-back program - Art 5 of MAR - Week 42 - 2023
- Ipsen updates on E.U. Marketing Authorisation Application for odevixibat in Alagille syndrome
- IPSEN - Buy-back programme - Art 5 of MAR - Week 40 - 2023
- Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
- Ipsen updates on QM-1114 regulatory process
- IPSEN - Buy-back programme - Art 5 of MAR - Week 38 - 2023
- IPSEN - Buy-back programme - Art 5 of MAR - Week 36 - 2023
- Ipsen announces change in R&D leadership: Howard Mayer to retire, succeeded by Christelle Huguet
- IPSEN - Buy-back programme - Art 5 of MAR - Week 33 - 2023
- Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
- IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2023
- IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2023
- Ipsen S.A. publishes its 2023 Half-Year Financial Report
- Ipsen announces a simplification of the concert of its principal shareholders representing 56.62% of the share capital and 72.36% of voting rights - effective from December 19, 2023
- Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
- Ipsen – Half year statement – 2023 06 30
- Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease
- Ipsen announces positive outcome of FDA Advisory Committee on investigational palovarotene for fibrodysplasia ossificans progressiva